Inovio Pharmaceuticals Inc. [INO] Stock trading around $2.79 per share: What’s Next?

Inovio Pharmaceuticals Inc. [NASDAQ: INO] closed the trading session at $2.79 on 08/15/22. The day’s price range saw the stock hit a low of $2.60, while the highest price level was $2.79. The company report on August 9, 2022 that INOVIO Reports Financial Results and Highlights for the Second Quarter 2022.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Increased Cash Runway into Third Quarter 2024 with Cost-Savings and Corporate Restructuring Efforts.

Strengthened Executive Team with Appointment of Dr. Michael Sumner as Chief Medical Officer.

The stocks have a year to date performance of -44.09 percent and weekly performance of 18.22 percent. The stock has been moved at -15.96 percent over the last six months. The stock has performed 41.62 percent around the most recent 30 days and changed 40.20 percent over the most recent 3-months.

If compared to the average trading volume of 6.97M shares, INO reached to a volume of 5282265 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Inovio Pharmaceuticals Inc. [INO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INO shares is $4.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INO stock is a recommendation set at 2.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Inovio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on July 19, 2022. The new note on the price target was released on May 11, 2022, representing the official price target for Inovio Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $8 to $10, while BofA Securities kept a Neutral rating on INO stock. On December 29, 2021, analysts decreased their price target for INO shares from 8 to 6.

The Average True Range (ATR) for Inovio Pharmaceuticals Inc. is set at 0.22, with the Price to Sales ratio for INO stock in the period of the last 12 months amounting to 309.92. The Price to Book ratio for the last quarter was 2.20, with the Price to Cash per share for the same quarter was set at 1.49.

INO stock trade performance evaluation

Inovio Pharmaceuticals Inc. [INO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.22. With this latest performance, INO shares gained by 41.62% in over the last four-week period, additionally sinking by -15.96% over the last 6 months – not to mention a drop of -69.77% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INO stock in for the last two-week period is set at 65.56, with the RSI for the last a single of trading hit 69.16, and the three-weeks RSI is set at 62.22 for Inovio Pharmaceuticals Inc. [INO]. The present Moving Average for the last 50 days of trading for this stock 1.98, while it was recorded at 2.52 for the last single week of trading, and 3.71 for the last 200 days.

Inovio Pharmaceuticals Inc. [INO]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Inovio Pharmaceuticals Inc. [INO] shares currently have an operating margin of -17535.79 and a Gross Margin at -166.56. Inovio Pharmaceuticals Inc.’s Net Margin is presently recorded at -17109.87.

Return on Equity for this stock declined to -70.55, with Return on Assets sitting at -58.26.

Inovio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.

Earnings per share (EPS) analysis for Inovio Pharmaceuticals Inc. [INO] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Inovio Pharmaceuticals Inc. go to 45.80%.

Inovio Pharmaceuticals Inc. [INO]: Insider Ownership positions

There are presently around $317 million, or 37.80% of INO stock, in the hands of institutional investors. The top three institutional holders of INO stocks are: STATE STREET CORP with ownership of 32,195,674, which is approximately 38.369% of the company’s market cap and around 1.20% of the total institutional ownership; BLACKROCK INC., holding 19,925,606 shares of the stock with an approximate value of $55.59 million in INO stocks shares; and VANGUARD GROUP INC, currently with $37.31 million in INO stock with ownership of nearly 18.881% of the company’s market capitalization.

Positions in Inovio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 93 institutional holders increased their position in Inovio Pharmaceuticals Inc. [NASDAQ:INO] by around 25,893,904 shares. Additionally, 71 investors decreased positions by around 3,844,254 shares, while 58 investors held positions by with 84,038,094 shares. The mentioned changes placed institutional holdings at 113,776,252 shares, according to the latest SEC report filing. INO stock had 21 new institutional investments in for a total of 351,324 shares, while 34 institutional investors sold positions of 796,664 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here